| Dr Ann M Gessner, DO | |
|
407 E Main St, Marshalltown, IA 50158-1928 | |
| (641) 752-4681 | |
| (641) 752-6572 |
| Full Name | Dr Ann M Gessner |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 28 Years |
| Location | 407 E Main St, Marshalltown, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598768269 | NPI | - | NPPES |
| #0207811 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | #3307 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Greeley Medical Center | Ames, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Doran And Doran Pc | 1456241983 | 6 |
News Archive
A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.
Global nanotechnology company pSivida Limited has announced that it's UK manufacturing partner, Atomising Systems Ltd ("ASL"), has reached a key milestone in the manufacture of BrachySil, its lead product, by completing construction of a state of the art dedicated cleanroom facility to GMP specifications at its Sheffield plant in the United Kingdom. ASL is a world leader in high temperature atomising technology.
Visual impairment that is not explained by refractive error is increasing, as is the prevalence of diabetes – particularly diabetes lasting 10 years or longer, show US study results.
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.
› Verified 2 days ago
| Entity Name | Doran & Doran Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417930736 PECOS PAC ID: 1456241983 Enrollment ID: O20040318000579 |
News Archive
A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.
Global nanotechnology company pSivida Limited has announced that it's UK manufacturing partner, Atomising Systems Ltd ("ASL"), has reached a key milestone in the manufacture of BrachySil, its lead product, by completing construction of a state of the art dedicated cleanroom facility to GMP specifications at its Sheffield plant in the United Kingdom. ASL is a world leader in high temperature atomising technology.
Visual impairment that is not explained by refractive error is increasing, as is the prevalence of diabetes – particularly diabetes lasting 10 years or longer, show US study results.
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ann M Gessner, DO 407 E Main St, Marshalltown, IA 50158-1928 Ph: (641) 752-4681 | Dr Ann M Gessner, DO 407 E Main St, Marshalltown, IA 50158-1928 Ph: (641) 752-4681 |
News Archive
A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.
Global nanotechnology company pSivida Limited has announced that it's UK manufacturing partner, Atomising Systems Ltd ("ASL"), has reached a key milestone in the manufacture of BrachySil, its lead product, by completing construction of a state of the art dedicated cleanroom facility to GMP specifications at its Sheffield plant in the United Kingdom. ASL is a world leader in high temperature atomising technology.
Visual impairment that is not explained by refractive error is increasing, as is the prevalence of diabetes – particularly diabetes lasting 10 years or longer, show US study results.
Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.
› Verified 2 days ago
Melissa Ann Koch, CNM Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 407 E Main St, Marshalltown, IA 50158 Phone: 641-752-4681 | |
Dr. Richard L Dowell, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 407 E Main St, Marshalltown, IA 50158 Phone: 641-752-4681 Fax: 641-752-6572 |